Short PDE4 Isoforms as Drug Targets in Disease
The second messenger, cyclic adenosine monophosphate (cAMP), is a master regulator of signal transduction that maintains cell homeostasis. A fine balance between cAMP synthesis by adenylyl cyclase and degradation by phosphodiesterases (PDEs) underpins receptor-specific responses. As multiple recepto...
Main Authors: | Elka Kyurkchieva, George S. Baillie |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR Press
2023-07-01
|
Series: | Frontiers in Bioscience-Landmark |
Subjects: | |
Online Access: | https://www.imrpress.com/journal/FBL/28/7/10.31083/j.fbl2807133 |
Similar Items
-
CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms
by: Egor B. Skryabin, et al.
Published: (2023-06-01) -
Functions of PDE3 Isoforms in Cardiac Muscle
by: Matthew Movsesian, et al.
Published: (2018-02-01) -
Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease
by: Jianwen Sheng, et al.
Published: (2022-10-01) -
The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons
by: Marina ePolito, et al.
Published: (2013-11-01) -
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
by: Dave Singh, et al.
Published: (2019-08-01)